Esperion Therapeutics, Inc.
ESPRNasdaq
$3.18
↓ -0.3%Jul 10 close · end-of-day
Price
1Y↑ +158.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
No screener snapshot for this ticker.
Company profile
Esperion Therapeutics, Inc. develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program.
- CEO
- Sheldon L. Koenig
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 200
- Headquarters
- Michigan
- Website
- esperion.com
Management & directors
- Halladay BenjaminChief Financial Officer
- Harlow John B. Jr.Chief Commercial Officer
- Koenig Sheldon L.President and CEO
- Looker BenjaminChief Legal Officer
Roles derived from SEC Form 4 filings.
Earnings
ESPR Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$80.1M↑ +23.2%
Diluted EPS-$0.10↓ -52.4%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $227.5M | $78.4M | $75.5M | $116.3M | $332.3M | $403.1M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$121.4M | -$226.7M | -$179.5M | -$155.6M | $54.4M | $60.3M |
| Net income | -$143.6M | -$269.1M | -$233.7M | -$209.2M | -$51.7M | -$22.7M |
| Diluted EPS | -$5.23 | -$9.31 | -$3.52 | -$2.03 | -$0.28 | -$0.11 |
| Operating cash flow | -$85.2M | -$263.8M | -$174.8M | -$135.5M | -$23.7M | -$13.1M |
| Free cash flow | -$86.0M | -$263.8M | -$174.8M | -$135.5M | -$24.0M | -$13.1M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -53.3% | -289.0% | -237.8% | -133.7% | 16.4% | 15.0% |
| Net margin | -63.1% | -343.0% | -309.6% | -179.9% | -15.6% | -5.6% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $73.8M | $51.6M | $69.1M | $65.0M | $82.4M | $87.3M | $168.4M | $80.1M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $2.6M | -$16.0M | -$4.4M | -$22.1M | $7.1M | -$10.0M | $85.2M | -$6.6M |
| Net income | -$61.9M | -$29.5M | -$21.3M | -$40.5M | -$12.7M | -$31.3M | $61.8M | -$25.2M |
| Diluted EPS | -$0.33 | -$0.15 | -$0.14 | -$0.21 | -$0.06 | -$0.16 | $0.32 | -$0.10 |
| Operating cash flow | -$7.2M | -$35.3M | -$35.0M | -$22.6M | -$31.4M | -$4.3M | $45.2M | -$27.7M |
| Free cash flow | -$7.3M | -$35.5M | -$35.0M | -$22.6M | -$31.4M | -$4.3M | $45.2M | -$27.9M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | 3.5% | -31.0% | -6.4% | -34.0% | 8.6% | -11.4% | 50.6% | -8.2% |
| Net margin | -83.9% | -57.2% | -30.8% | -62.2% | -15.4% | -35.9% | 36.7% | -31.5% |
Company news
Jul 10, 2026
Jun 23, 2026
Jun 10, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-13 | CARROLL J MARTIN | D | 177,523 | — | — | filing |
| 2026-07-13 | HOFFMAN ROBERT | D | 85,153 | — | — | filing |
| 2026-07-13 | Shepard Jay | D | 164,472 | — | — | filing |
| 2026-07-13 | Fischer Seth H. Z. | D | 141,023 | — | — | filing |
| 2026-07-13 | THOMPSON JOHN CRAIG | D | 79,873 | — | — | filing |
| 2026-07-13 | Harlow John B. Jr.· Chief Commercial Officer | D | 424,536 | — | — | filing |
| 2026-07-13 | Looker Benjamin· Chief Legal Officer | D | 667,524 | — | — | filing |
| 2026-07-13 | Halladay Benjamin· Chief Financial Officer | D | 705,410 | — | — | filing |
| 2026-07-13 | Koenig Sheldon L.· President and CEO | D | 2,121,094 | — | — | filing |
| 2026-06-17 | Koenig Sheldon L.· President and CEO | Sale | 53,588 | $3.16 | $169,070.14 | filing |
| 2026-06-17 | Looker Benjamin· Chief Legal Officer | Sale | 11,824 | $3.16 | $37,304.72 | filing |
| 2026-06-17 | Halladay Benjamin· Chief Financial Officer | Sale | 10,773 | $3.16 | $33,988.82 | filing |
| 2026-05-28 | Shepard Jay | Award | 79,873 | $0.00 | $0.00 | filing |
| 2026-05-28 | THOMPSON JOHN CRAIG | Award | 79,873 | $0.00 | $0.00 | filing |
| 2026-05-28 | HOFFMAN ROBERT | Award | 79,873 | $0.00 | $0.00 | filing |
| 2026-05-28 | Fischer Seth H. Z. | Award | 79,873 | $0.00 | $0.00 | filing |
| 2026-05-28 | CARROLL J MARTIN | Award | 79,873 | $0.00 | $0.00 | filing |
| 2026-03-17 | Koenig Sheldon L.· President and CEO | Sale | 25,578 | $2.72 | $69,546.58 | filing |
| 2026-03-17 | Halladay Benjamin· Chief Financial Officer | Sale | 6,424 | $2.71 | $17,376.92 | filing |
| 2026-03-17 | Looker Benjamin· Chief Legal Officer | Sale | 5,708 | $2.70 | $15,428.72 | filing |
| 2026-03-13 | Halladay Benjamin· Chief Financial Officer | Award | 247,430 | $0.00 | $0.00 | filing |
| 2026-03-13 | Looker Benjamin· Chief Legal Officer | Award | 300,840 | $0.00 | $0.00 | filing |
| 2026-03-13 | Koenig Sheldon L.· President and CEO | Award | 723,760 | $0.00 | $0.00 | filing |
| 2026-01-20 | Looker Benjamin· General Counsel | Sale | 1,689 | $2.88 | $4,867.70 | filing |
| 2025-12-17 | Koenig Sheldon L.· President and CEO | Sale | 48,244 | $3.67 | $177,200.21 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.